1. Home
  2. HEQ vs CLLS Comparison

HEQ vs CLLS Comparison

Compare HEQ & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Hedged Equity & Income Fund of Beneficial Interest

HEQ

John Hancock Hedged Equity & Income Fund of Beneficial Interest

N/A

Current Price

$10.98

Market Cap

136.8M

Sector

Finance

ML Signal

N/A

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$1.01

Market Cap

139.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HEQ
CLLS
Founded
N/A
1999
Country
United States
France
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.8M
139.0M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
HEQ
CLLS
Price
$10.98
$1.01
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $4.45
AVG Volume (30 Days)
17.7K
★ 64.3K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.50
$0.88
52 Week High
$12.00
$5.45

Technical Indicators

Market Signals
Indicator
HEQ
CLLS
Relative Strength Index (RSI) 38.51 39.96
Support Level $10.85 $0.94
Resistance Level $11.60 $1.28
Average True Range (ATR) 0.17 0.12
MACD -0.03 0.01
Stochastic Oscillator 5.37 4.87

Price Performance

Historical Comparison
HEQ
CLLS

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return, with a focus on current income and gains, and to include long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: